Is GH Research PLC (GHRS) a Buy, Sell, or Hold?
GH Research PLC
NASDAQ:GHRS
$26.77 USD
$1.42 (5.6%)
- Volume
- 98.07K
- Average Volume
- 263.81K
- Market Capitalization
- $1.84B
- P/E Ratio
- -29.10
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $28.96
- Year Low
- $11.32
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $23.04
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Velichka Valcheva |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GHRS |
| CUSIP | G3855L106 |
| CIK | 0001855129 |
| Web | https://www.ghres.com |
| Phone | 353 1 437 8443 |
| Currency | USD |
| Employees | 73 |
| Country | IE |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 23.04 |
| Quick Ratio | 23.04 |
| Cash Ratio | 20.54 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.75 |
| Price / Cash Flow | -39.46 |
| Price / Book | 6.31 |
Price Target and Rating
| Average Stock Price Forecast | $35.00 |
| High Stock Price Forecast | $65.00 |
| Low Stock Price Forecast | $32.00 |
| Forecast Upside/Downside | -23.51% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.79 |
| Trailing P/E Ratio | -29.10 |
| PEG Ratio | 1.72 |
| P/E Growth | 1.72 |
| Net Income | $-48.26M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -19.83% |
| Return on Assets | -20.49% |
Financials Score
| AltmanZ Score | 87.06 |
| Piotroski Score | 1.00 |
| Working Capital | 260.42M |
| Total Assets | 275.27M |
| Ebit | -56.21M |
| Market Cap | 1.73B |
| Total Liabilities | 11.89M |
Poll Results
About GH Research PLC (NASDAQ:GHRS) Stock
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disor ... ders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
CleanSpark shares surge after company secures $6.6B data center lease agreement
2026-07-14 07:53:00
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
2026-07-14 07:20:00
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
2026-07-13 15:18:27
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.
GH Research Announces Publication of Phase 2a Postpartum Depression Results
2026-06-04 07:00:00
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” has been published in The Journal of Clinical Psychiatry (DOI: 10.4088/JCP.25m16284).
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
2026-05-20 04:07:05
GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling it remains to be seen how the drug stacks up against peers under real-world conditions.
These Analysts Revise Their Forecasts On GH Research After Q1 Results
2026-05-15 10:58:23
GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 07:00:00
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Updates Scientific Presentations and Publications In March 2026, the results of our Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry.
GH Research Announces Pricing of $117.5 Million Underwritten Offering
2026-04-29 08:00:00
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares are being offered by GH Research PLC.
Frequently Asked Questions
-
What is the current GH Research PLC (GHRS) stock price?
-
GH Research PLC(NASDAQ:GHRS) stock price is $26.77 in the last trading session. During the trading session, GHRS stock reached the peak price of $28.96 while $11.32 was the lowest point it dropped to. The percentage change in GHRS stock occurred in the recent session was 5.6% while the dollar amount for the price change in GHRS stock was $1.42.
-
GHRS's industry and sector of operation?
-
The NASDAQ listed GHRS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GHRS?
-
Aaron Cameron | Chief Operating Officer
Florian Schonharting | Co-Founder & Non-Executive Chairman of the Board
Magnus Halle | Co-Founder & MD of Ireland
Julie Ryan | Vice President of Finance
Velichka Valcheva | Chief Executive Officer -
How many employees does GHRS have?
-
Number of GHRS employees currently stands at 73. GHRS operates from 28 Baggot Street Lower, Dublin, DU D02 NX43, IE.
-
Link for GHRS official website?
-
Official Website of GHRS is: https://www.ghres.com
-
How do I contact GHRS?
-
GHRS could be contacted at phone #353 1 437 8443 and can also be accessed through its website. GHRS operates from 28 Baggot Street Lower, Dublin, DU D02 NX43, IE.
-
How many shares of GHRS are traded daily?
-
The average number of GHRS shares traded daily for last 3 months was 263.81K.
-
What is the market cap of GHRS currently?
-
The market value of GHRS currently stands at $1.84B with its latest stock price at $26.77